{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-250674","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.399101+00:00","generated_at":"2026-05-17T02:09:43.556922+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FT819 SLE data: 10 patients show durable responses; expansion cohorts; pivotal study planned 2026","bullets":["10 SLE patients treated; 2 with lupus nephritis achieved CRR at 6 months; 1 in DORIS at 15 months.","No dose-limiting toxicities, low-grade CRS, no ICANS or GvHD; supports same-day discharge plans.","Initiated dose-expansion cohorts in AAV, IIM, and SSc; engaging FDA for registrational study design with pivotal study goal in 2026.","Approximately 600 cryopreserved FT819 bags in inventory available for patient treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-250674","json":"https://secwatch.observer/filing/0001193125-25-250674.json","markdown":"https://secwatch.observer/filing/0001193125-25-250674.md","text":"https://secwatch.observer/filing/0001193125-25-250674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525250674/0001193125-25-250674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525250674/d36426d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:09:43.556922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}